| Literature DB >> 31286997 |
Min Xu1, Jiacai He1, Chengfei Zhang2, Jianguang Xu3,4, Yuanyin Wang5.
Abstract
Accumulating evidence demonstrates that pre-vascularization of tissue-engineered constructs can significantly enhance their survival and engraftment upon transplantation. Endothelial cells (ECs), the basic component of vasculatures, are indispensable to the entire process of pre-vascularization. However, the source of ECs still poses an issue. Recent studies confirmed that diverse approaches are available in the derivation of ECs for tissue engineering, such as direct isolation of autologous ECs, reprogramming of somatic cells, and induced differentiation of stem cells in typology. Herein, we discussed a variety of human stem cells (i.e., totipotent, pluripotent, multipotent, oligopotent, and unipotent stem cells), which can be induced to differentiate into ECs and reviewed the multifarious approaches for EC generation, such as 3D EB formation for embryonic stem cells (ESCs), stem cell-somatic cell co-culture, and directed endothelial differentiation with growth factors in conventional 2D culture.Entities:
Keywords: 3D EB formation; Endothelial cells; Human stem cells; Tissue engineering
Mesh:
Year: 2019 PMID: 31286997 PMCID: PMC6615090 DOI: 10.1186/s13287-019-1274-1
Source DB: PubMed Journal: Stem Cell Res Ther ISSN: 1757-6512 Impact factor: 6.832
Fig. 1Stem cell-based strategies for human endothelial cell derivation
hESCs and hiPSCs strategies for human endothelial cell derivation
| Study | Cell line | Induction system | Purification method | Culture milieu | Induction Period (days) | Efficiency | Positive control | In vitro analysis | In vivo analysis | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medium | Growth factors | Other special factors | EC markers analyzed | Application/functional assessment | ||||||||
| Levenberg et al. [ | hESCs:H9 | 3D EB formation | PECAM1 (FACS) | EGM-2 | EGM-2 supplements | No | 13–15 | 2% of total cell population | HUVEC | Genes analysis for PECAM1, VE-cad, CD34, Flk-1, Tie-2 Protein analysis for PECAM1, VE-cad, vWF | In vitro Matrigel sprouting assay LDL uptake assay | Transplantation into SCID mice |
| Goldman et al. [ | hESCs:H9 | 3D EB formation | CD144/KDR (FACS) | knockout DMEM | IL-3, IL-6, G-CSF, Flt-3, SCF | BMP4 | 12 | More than 12% of total cell population | HUVEC | Genes analysis for CD144, KDR Protein analysis for CD144, KDR, CD31, CD34, vWF | In vitro Matrigel sprouting assay Migration assay in response to a VEGF gradient | No |
| Kim et al. [ | hESCs: CHA-3; | 3D EB formation | No | DMEM+F12 (50% respectively) | No | No | 15 | – | No | Genes analysis for PECAM1, Flk-1, Tie-2 Protein analysis for PECAM1, vWF | In vitro Matrigel sprouting assay LDL uptake assay | No |
| Figueiredo et al. [ | hESCs:H1 | 2D cells-co-culture system | No | 훼-MEM | No | No | 9 | (CD31+) 18.45% of total cell population | – | Protein analysis for CD31, KDR, CD144 | Vascular tube-like structure formation | No |
| Lippmann et al. [ | hESCs:H9 | 2D cells-co-culture system | No | 7 days unconditioned medium, 6 days EC medium | – | – | 13 | (PECAM-1+) 63% of total cell population | No | Genes analysis for PECAM1, vWF, VE-cad Protein analysis for PECAM1, vWF, VE-cad | LDL uptake assay In vitro Matrigel sprouting assay | No |
| Orlova et al. [ | hESCs: HES3; HES4 | 2D growth factor-supplemented differentiation system | CD31 (MACS) | mTeSR1 culture medium | VEGF-A; BMP4; Activin A | CHIR; SB431542 | 10 | (VE-Cad/CD31+) 19.9% of total cell population | No | Protein analysis for CD31, VE-cad, vWF | Tube formation assay | Zebrafish xenotransplantation assay |
| Kane et al. [ | hESCs:SA461; SA121 | 2D growth factor-supplemented differentiation system | No | Large vessel endothelial growth media | Hydrocortisone, EGF, bFGF, heparin | – | 14 | (VE-Cad/CD31+) 57.04% of total cell population | HUVEC HSVEC HMVEC | Gene analysis for CD31, Flt-1, KDR, VE-cad, CD34 Protein analysis for CD31, VE-cad; | NO production assay Tube formation assay | Transplantation into immunocompromised mice |
| Elcheva, I. et al. [ | hESCs:H1; H9 | 2D genetic manipulation system | No | mTeSR1 culture medium | – | – | 5 | Not clear | No | Protein analysis for CD31, VE-cad, vWF, CD34, CD73, KDR | LDL uptake assay Tube formation assay | No |
| Lindgren et al. [ | hESCs | Genetic manipulation combined with EB formation | No | DMEM+F12 | VEGF; bFGF2 | – | 7 | Not clear | No | Gene analysis for CD31, KDR, VE-cad Protein analysis for CD31, KDR, VE-cad | In vitro Matrigel sprouting assay; | No |
| Adams et al. [ | hiPSCs | 3D EB formation | VE-cad (MACS) | – | – | Fetal calf serum | 10 | About 18% of total cell population | No | Gene analysis for CD31, KDR, VE-cad Protein analysis for CD31, KDR, VE-cad, eNOS | LDL uptake assay In vitro Matrigel sprouting assay | No |
| Lin et al. [ | hiPSCs | 3D EB formation with addition of growth factors | KDR (FACS) | EGM2 | VEGF bFGF | – | 20 | About 20% of total cell population | No | Genes analysis for KDR, CD31 Protein analysis for CD31, VE-cad | LDL uptake assay In vitro Matrigel sprouting assay | Matrigel plug assay in NOD/SCID mice |
| Choi et al. [ | hiPSCs | 2D cell-co-culture system | CD34 (MACS) with CD31 (FCAS) | 훼-MEM | – | – | 8 | 2.8%~ 6.0% of total cell population | No | Protein analysis for CD31, KDR, CD49d, CD105, CD144, CD146, vWF, VE-cad | Tube formation assay | No |
Adult stem cells strategies for human endothelial cell derivation
| Study | Cell line | Induction system | Purification method | Culture milieu | Induction period (days) | Efficiency | Positive control | In vitro analysis | In vivo analysis | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medium | Growth factors | Other special factors | EC markers analyzed | Application/functional assessment | ||||||||
| Zhang et al. [ | DPSCs | In vivo differentiation system | No | No | No | No | 4 weeks | No | HDMEC | Protein analysis for cd31 | No | Blood vessel formation in mice |
| Joddar et al. [ | BMMSCs | Co-culture system (with fixed ECs/with EC matrix) | No | EBM-2 | No | No | 7 days | About 70% out of total cells | No | Protein analysis for CD31 | No | No |
| Lozito et al. [ | BMMSCs | Co-culture system (direct MSC-EC co-culture/indirect MSC-EC co-Culture/with EC matrix) | DiI-labeled FACS sorting | EGM-2-MV | VEGF | – | 10 days | No | No | Gene analysis for PECAM Protein analysis for PECAM | Tube formation on Matrigel | No |
| Gong et al. [ | SHED | Co-culture system (with EC matrix) | No | EGM-2-MV | VEGF | – | 14 days | No | No | Gene analysis for CD31, VEGFR2, VWF | Tube formation on Matrigel | No |
| Oswald, J. et al. [ | BMMSCs | Growth factor system | No | DMEM | VEGF | – | 7 days | Not clear | No | Protein analysis for KDR, VE-cad, Flt1, vWF | Tube formation on Matrigel | No |
| Lloyd-Griffith et al. [ | AFSCs | Growth factor system | No | EndoGroTM-VEGF complete media | VEGF hFGF EGF et al. | – | 14 days | No | HUVECs | Gene analysis for CD31, VEGFR2, VWF, Angiopoietin 1 Protein analysis for CD31; | In vitro Matrigel sprouting assay LDL uptake assay | No |
| Xu et al. [ | SHED/DPSCs | Growth factor system | No | EGM | VEGF | SB-431542 | 14 days | No | No | Gene analysis for VEGFR1, VEGFR2, CD31, Tie-2, EphrinB2 Protein analysis for CD31, VEGFR2 | In vitro Matrigel sprouting assay | Matrigel plug assay |
| Yuan et al. [ | hMSCs | Mechanical stimuli system | No | DMEM | bFGF | No | 7 days | No | No | Protein analysis for CD31, VE-cadherin, vWF | No | No |
| Wu et al. [ | PDMCs | Mechanical stimuli system | No | EGM | VEGF | No | 4 days | No | No | Gene analysis for Flt-1, Flk-1, vWF, PECAM-1 Protein analysis for vWF, PECAM-1 | LDL uptake assay Tube formation on Matrigel | No |